Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

Phase 2Enrolling By InvitationNCT06657859

Glycomine, Inc.40 enrolled

Overview

The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials. It will also learn about the long term safety of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.

This is a phase 2 open-label clinical study of GLM101 in patients with PMM2-CDG who have previously participated in a study of GLM101. This study is designed to monitor long-term safety and treatment effect of GLM101 and provided continued access to study treatment. Participants will continue weekly infusions of GLM101 at the same dose level they received in the previous study. Dose levels may be adjusted to lower doses or higher doses based on available data that demonstrates a change to be safe and tolerable. Participants will be asked to complete questionnaires to evaluate changes in ataxia and quality of life.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pmm2-CDG Phosphomannomutase 2 Deficiency

Interventions

GLM101DRUG

GLM101 IV infusion

Eligibility

Sex: ALLMin age: 2 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and able to provide informed consent/assent and/or their legally authorized representative * Completed previous clinical study with GLM101 * If female of childbearing potential, must not be pregnant and use a medically accepted method of contraception * If male and sexually active must agree to use a medically acceptable method of contraception * Willing ad able to adhere to study requirements described in the protocol Exclusion Criteria: * Has a condition that would compromise safety or compliance of participant or preclude participant completion of study * Has positive serum pregnancy test * Unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions.

Locations (1)

Hospital Sant Joan de Déu

Barcelona, Spain

Outcomes

Primary Outcomes

Evaluate long-term safety

Number of participants with treatment related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Time frame: From enrollment to end of treatment up to 4 years

Secondary Outcomes

Evaluate changes in ataxia using International Cooperative Ataxia Rating Scale (ICARS)

The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment.

Time frame: From enrollment, at 3 months, 6 months and annually to end of treatment up to 4 years

Maximum observed plasma concentration (Cmax)

Assessment of the pharmacokinetics (PK) of GLM101

Time frame: From enrollment to end of treatment up to 4 years

Time to maximum observed plasma concentration (Tmax)

Assessment pharmacokinetics (PK) of GLM101

Time frame: From enrollment to end of treatment up to 4 years

Area under the plasma concentration vs. time curve (AUC)

Assessment of the pharmacokinetics (PK) of GLM101

Time frame: From enrollment to end of treatment up to 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.